Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of mRNA-3927 in Propionic Acidemia
jRCT2043250110Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Apr 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3927 in propionic acidemia (PA), sponsored by Moderna Inc. Primary endpoint: Long-term efficacy: frequency of metabolic decompensation events (MDEs). Started Apr 2025; status: recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on jRCT2043250110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043250110.